Debiopharm

Executive Summary

Debiopharm is a Swiss private biopharmaceutical company with over four decades of experience in developing innovative therapies for oncology and bacterial infections. The company operates across drug development, manufacturing, and digital health investments, with a focus on improving patient outcomes. Debiopharm's business model includes in-licensing promising assets, advancing them through clinical development, and out-licensing or partnering for commercialization. The company has built a diverse pipeline spanning small molecules and biologics, with several programs in mid-to-late-stage clinical trials. Key areas include targeted cancer therapies and novel antibiotics to address antimicrobial resistance. Despite being privately held, Debiopharm has established a strong track record of partnerships with major pharmaceutical companies, reflecting confidence in its R&D capabilities and asset quality.

Upcoming Catalysts (preview)

• Q2 2026Phase 3 data readout for lead oncology candidate65% success
• Q4 2026Regulatory submission for novel antibiotic against resistant infections70% success
• Q3 2026New partnership or licensing deal for digital health platform50% success